Characterization of bleeding in thrombotic thrombocytopenic purpura in the precaplacizumab era: a retrospective nationwide analysis.

ABSTRACT:

Background

The addition of caplacizumab to immune thrombotic thrombocytopenia (iTTP) treatment options has led to a renewed interest in characterizing the epidemiology and risk factors for bleeding in iTTP. Limited data exist on the bleeding risk in iTTP due to systemic underreporting in earlier cohorts.

Objectives

To describe the incidence, patterns, and predictors of bleeding in hospitalized iTTP patients independent of caplacizumab use.

Methods

We retrospectively analyzed the National Inpatient Sample database (2012-2019) and identified adult patients with a diagnosis of iTTP. Predictors of bleeding were determined by multivariable logistic regression analysis.

Results

We identified 3103 iTTP hospitalizations; bleeding occurred in 594 (19.1%), and 157 (5.1%)

SUBMITTER: Mahmoud AA 

PROVIDER: S-EPMC11742298 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature